Business Context and Reporting Period
This Form 6-K filing by AC Immune SA reports the results of the Annual Ordinary Shareholders' Meeting held on November 15, 2016. The filing covers corporate governance actions, financial approvals for the fiscal year 2015, and compensation mandates for the period extending to June 2017.
Key Financial Metrics
The filing provides specific figures regarding the appropriation of gains for the 2015 fiscal year:
- Net Profit (2015): KCHF 20,173
- Loss Brought Forward (Pre-appropriation): KCHF 45,103
- Loss Brought Forward (Post-appropriation): KCHF 24,930
The filing text does not provide clear values for revenue, operating cash flow, margins, debt levels, or liquidity ratios for the reporting period.
Material Changes and Corporate Actions
Shareholders approved several material changes and governance updates:
- Financial Statements: Approval of the Annual Report and Consolidated Financial Statements for 2015 under IFRS.
- Board Composition: Re-election of Martin Velasco (Chairman), Peter Bollmann, Friedrich von Bohlen, Andrea Pfeifer, and Detlev Riesner. Thomas Graney was elected as a new Board member.
- Equity Plan: Approval of the 2016 Stock Option and Incentive Plan, authorizing a maximum of 2,057,740 options for common shares.
- Auditor: Re-election of Ernst & Young SA for a one-year term.
Guidance, Outlook, and Compensation
While no forward-looking financial guidance is provided, the filing details approved compensation caps for the period from November 15, 2016, to June 30, 2017:
- Board of Directors (Non-performance cash): CHF 286,080
- Board of Directors (Equity): CHF 460,000
- Executive Committee (Non-performance cash): CHF 836,790
- Executive Committee (Variable cash for 2016): CHF 667,000
- Executive Committee (Equity): CHF 2,001,000
The filing does not explicitly list new risks, contingencies, or unusual items beyond the standard corporate governance approvals.
Investor Verification Checklist
- Verify the full text of the 2015 Annual Financial Statements (Exhibit 99.1) to assess revenue and cash flow trends not detailed in this summary.
- Confirm the impact of the 2,057,740 new stock options on potential share dilution.
- Review the specific terms of the 2016 Stock Option and Incentive Plan for vesting schedules and exercise prices.
- Monitor the company's burn rate given the continued existence of a KCHF 24,930 loss brought forward.